City Therapeutics, Inc. announces the first participant has been dosed in a Phase 1 clinical trial for CITY-RBP4, targeting Stargardt disease.
| Name | CITY THERAPEUTICS, INC. |
|---|---|
| CIK | 0002143850 |
| Tickers | CTY |
| Exchanges | Nasdaq |
| Entity type | other |
| Category | <br>Emerging growth company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 932762122 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 857-357-2024 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
City Therapeutics, Inc. announces the first participant has been dosed in a Phase 1 clinical trial for CITY-RBP4, targeting Stargardt disease.
FMR LLC reports a 14% ownership stake in City Therapeutics, signaling strong investor interest in the pharmaceutical sector.
Viking Global Investors has disclosed a 7% stake in City Therapeutics, signaling growing interest in the pharmaceutical sector.
ARCH Venture Fund XII, L.P. acquires 25.6% of City Therapeutics, Inc., indicating strong investor interest in the pharmaceutical preparations sector.
City Therapeutics, Inc. files a Schedule 13G, indicating changes in beneficial ownership, reflecting strategic investment shifts in the pharmaceutical sector.
City Therapeutics, Inc. director Sara Nochur acquires 22,649 stock options, reflecting confidence in the company's future growth in the pharmaceutical sector.
City Therapeutics, Inc. director John Maraganore acquires over 610,000 shares, signaling confidence in the company's future amid industry developments.
City Therapeutics, Inc. announces significant stock transactions involving Robert Nelsen, highlighting investor confidence in the pharmaceutical sector.
City Therapeutics, Inc. grants stock options to director Barry E. Greene, reflecting a strategic move to align interests with shareholders.
City Therapeutics, Inc. reports significant stock transactions by ARCH Venture Partners, indicating a shift in ownership stakes in the pharmaceutical sector.
City Therapeutics, Inc. disclosed a stock option transaction by director Philip Ron M, highlighting its commitment to incentivizing key personnel.
City Therapeutics reports CEO Andrew C. Orth exercised stock options, reflecting the company's growth strategy in the pharmaceutical preparations sector.
City Therapeutics has amended its bylaws and certificate of incorporation, signaling a new phase in its corporate governance and potential growth.
City Therapeutics, Inc. filed an amended S-1 registration statement for its IPO, aiming to raise funds and list on Nasdaq under the ticker 'CTY.'
34 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-10 | 8-K | FORM 8-K | 7.01,9.01 | 0001104659-26-124775 | 001-43510 | 261537917 | 34 | 215182 | 1 | 1 |
| 2026-11-06 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002961 | 005-95976 | 261529792 | 34 | 11489 | |||
| 2026-10-26 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001193125-26-432028 | 005-95976 | 261486365 | 34 | 41715 | |||
| 2026-10-26 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000905148-26-004557 | 005-95976 | 261486200 | 34 | 35680 | |||
| 2026-10-22 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002005369-26-000056 | 005-95976 | 261478286 | 34 | 25463 | |||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116966 | 27096 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116965 | 20569 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116963 | 13254 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116962 | 5523 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116959 | 5535 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116958 | 5530 | ||||||
| 2026-10-19 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-116956 | 5585 | ||||||
| 2026-10-19 | 8-K | FORM 8-K | 5.03,9.01 | 0001104659-26-116947 | 001-43510 | 261469851 | 34 | 428692 | 1 | 1 |
| 2026-10-16 | S-8 | FORM S-8 | 0001104659-26-116637 | 333-299504 | 261466723 | 33 | 236379 | 1 | 1 | |
| 2026-10-16 | 424B4 | 424B4 | 0001104659-26-116636 | 333-299117 | 261466710 | 33 | 6593024 | |||
| 2026-10-15 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-003256 | 333-299117 | 261464246 | 33 | 1698 | ||
| 2026-10-15 | S-1MEF | S-1MEF | 0001104659-26-116363 | 333-299481 | 261464213 | 33 | 194556 | 1 | 1 | |
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116360 | 17974 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116359 | 13689 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116358 | 11833 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116357 | 9849 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116355 | 10131 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116353 | 11881 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116352 | 10121 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116351 | 14314 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116350 | 11861 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116349 | 14979 | ||||||
| 2026-10-15 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-116348 | 9983 | ||||||
| 2026-10-15 | CERT | CTY_8A_Cert_2143850.pdf | 0001354457-26-000991 | 001-43510 | 261463230 | 34 | 564165 | |||
| 2026-10-13 | 8-A12B | 8-A12B | 0001104659-26-115485 | 001-43510 | 261456880 | 34 | 15911 | |||
| 2026-10-09 | S-1/A | S-1/A | 0001104659-26-114815 | 333-299117 | 261451088 | 33 | 8058196 | 1 | 1 | |
| 2026-09-24 | S-1 | S-1 | 0001104659-26-110430 | 333-299117 | 261405168 | 33 | 10700695 | 1 | 1 | |
| 2026-08-24 | DRS/A | filename1.htm | 0001104659-26-099793 | 377-09568 | 261306190 | 33 | 8133281 | |||
| 2026-07-15 | DRS | filename1.htm | 0001104659-26-083608 | 377-09568 | 261175525 | 33 | 5622624 |
One latest value per concept from companyfacts (5 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ffd | NetFeeAmt | NetFeeAmt | USD | 12,526.06 | 2026-10-16 | S-8 | 2026-10-16 | 0001104659-26-116637 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 12,526.06 | 2026-10-16 | S-8 | 2026-10-16 | 0001104659-26-116637 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 143.98M | 2026-10-16 | S-8 | 2026-10-16 | 0001104659-26-116637 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-16 | S-8 | 2026-10-16 | 0001104659-26-116637 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-15 | S-1MEF | 2026-10-15 | 0001104659-26-116363 |